Granata Bio | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Granata Bio is a biopharmaceutical company based in the U.S., founded in 2018, that specializes in women's health, particularly in infertility and reproductive health. The company is dedicated to identifying, in-licensing, and developing innovative fertility therapeutics to meet the needs of the reproductive health market in North America. With a team that has over 75 years of combined experience in clinical development and regulatory affairs, the organization focuses on ensuring safety, efficacy, and compliance in its therapeutic offerings.

Core activities include the development and commercialization of fertility therapeutics that support the entire IVF treatment cycle, from ovarian stimulation to luteal phase support. A notable advancement is the acquisition of Oviva Therapeutics, which introduced OVI-586, a novel therapeutic candidate aimed at addressing ovarian aging. Strategic partnership with Gedeon Richter Plc. enhances market presence and co-development of fertility products for the U.S. The organization is committed to improving patient experiences and clinical outcomes in the rapidly evolving field of reproductive health.